Login to Your Account



Clinic Roundup


Monday, November 21, 2011
• Tonix Pharmaceuticals Holding Corp., of New York, said the FDA cleared its investigational new drug application for a comparative pharmacokinetic and bioavailability study of TNX-102, an oral formulation of cyclobenzaprine for treating fibromyalgia syndrome.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription